Elevated Plasma IL-38 Concentrations in Patients with Acute ST-Segment Elevation Myocardial Infarction and Their Dynamics after Reperfusion Treatment

• Published in: Mediators of Inflammation Vol. 2015; no. 2015; pp. 433 - 442-239
• Main Authors: Ji, Qing-wei, Wang, Xiaoya, Wang, Xiang, Yu, Kunwu, Zhong, Yucheng, Zeng, Qiu-tang
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 01-01-2015; Hindawi Publishing Corporation; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Acute coronary syndromes; Adult; Age; Aged; Biomarkers; C-Reactive Protein - analysis; Cardiology; Cardiovascular disease; Colleges & universities; Coronary vessels; Cytokines; Diabetes; Electrocardiography; Female; Gene expression; Health aspects; Heart attack; Heart attacks; Hospitals; Humans; Inflammation; Interleukins; Interleukins - blood; Laboratories; Male; Medical imaging; Middle Aged; Myocardial Infarction - immunology; Myocardial Infarction - therapy; Myocardial Reperfusion; Natriuretic Peptide, Brain - blood; Natriuretic peptides; Pain; Peptide Fragments - blood; Physiological aspects; Plasma; Proteins; Science; Troponin I - blood; Womens health
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2015/490120

Objective. Recent studies suggest that IL-38 is associated with autoimmune diseases. Furthermore, IL-38 is expressed in human atheromatous plaque. However, the plasma levels of IL-38 in patients with ST-segment elevation myocardial infarction (STEMI) have not yet to be investigated. Methods. On admission, at 24 h, at 48 h, and at 7 days, plasma IL-38, C-reactive protein (CRP), cardiac troponin I (cTNI), and N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) levels were measured and IL-38 gene in peripheral blood mononuclear cells (PBMCs) was detected in STEMI patients. Results. The results showed that plasma IL-38 levels and IL-38 gene expression in PBMCs were significantly increased in STEMI patients compared with control group and were time dependent, peaked at 24 h. In addition, plasma IL-38 levels were dramatically reduced in patients with reperfusion treatment compared with control group. Similar results were also demonstrated with CRP, cTNI, and NT-proBNP levels. Furthermore, IL-38 levels were found to be positively correlated with CRP, cTNI, and NT-proBNP and be weakly negatively correlated with left ventricular ejection fraction (LVEF) in STEMI patients. Conclusions. The results indicate that circulating IL-38 is a potentially novel biomarker for patients with STEMI and IL-38 might be a new target for MI study.